Verona Pharma PLC
VRNA68.350USD
+2.890+4.41%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
46.27BCap. mercado
PérdidaP/E TTM
Más Datos de Verona Pharma PLC Compañía
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Información de la empresa
Código de la empresaVRNA
Nombre de la empresaVerona Pharma PLC
Fecha de salida a bolsaMar 30, 2005
Fundada en2005
Director ejecutivoDr. David S. Zaccardelli
Número de empleados209
Tipo de seguridadDepository Receipt
Fin del año fiscalMar 30
DirecciónRiverside
CiudadLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Teléfono442032834200
Sitio Webhttps://www.veronapharma.com/
Código de la empresaVRNA
Fecha de salida a bolsaMar 30, 2005
Fundada en2005
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Director
Non-Executive Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Director
Non-Executive Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
11.51M
+1.80K%
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
10.60M
+4.02K%
Ms. Claire Louise Poll
Ms. Claire Louise Poll
General Counsel
General Counsel
541.81K
--
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
+700.00%
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: vie., 28 de mar
Hora de actualización: vie., 28 de mar
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
Estadísticas de accionistas
Accionista
Proporción
Zaccardelli (David S)
13.55%
Hahn (Mark W)
12.48%
Perceptive Advisors LLC
7.52%
New Enterprise Associates (NEA)
4.81%
Frazier Life Sciences Management, L.P.
3.98%
Other
57.67%
Tipo
Accionista
Proporción
Individual Investor
35.16%
Investment Advisor/Hedge Fund
22.11%
Hedge Fund
21.55%
Investment Advisor
15.58%
Private Equity
11.64%
Venture Capital
7.78%
Research Firm
2.44%
Family Office
1.04%
Bank and Trust
0.28%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
341
98.98M
116.47%
+16.60M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Zaccardelli (David S)
11.51M
13.55%
+10.91M
+1.80K%
Mar 01, 2025
Hahn (Mark W)
10.60M
12.48%
+10.34M
+4.02K%
Mar 01, 2025
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
Maverick Capital, Ltd.
3.13M
3.68%
-1.09M
-25.79%
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
Vivo Capital, LLC
2.28M
2.69%
-1.27M
-35.66%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
AdvisorShares Dorsey Wright ADR ETF
6.2%
ALPS Medical Breakthroughs ETF
4.7%
ProShares Ultra Nasdaq Biotechnology
0.5%
First Trust IPOX Europe Equity Opportunities ETF
0.49%
Invesco Nasdaq Biotechnology ETF
0.49%
iShares Biotechnology ETF
0.3%
Goldman Sachs Innovate Equity ETF
0.16%
Eventide US Market ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Long/Short Equity ETF
0%
Ver más
AdvisorShares Dorsey Wright ADR ETF
Proporción6.2%
ALPS Medical Breakthroughs ETF
Proporción4.7%
ProShares Ultra Nasdaq Biotechnology
Proporción0.5%
First Trust IPOX Europe Equity Opportunities ETF
Proporción0.49%
Invesco Nasdaq Biotechnology ETF
Proporción0.49%
iShares Biotechnology ETF
Proporción0.3%
Goldman Sachs Innovate Equity ETF
Proporción0.16%
Eventide US Market ETF
Proporción0.09%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
First Trust Long/Short Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos